4BIO Ventures II | 4biocapital

HOME
ABOUT US
- SOCIAL IMPACT
STRATEGY
TEAM
PORTFOLIO
- VENTURE PORTFOLIO
- PAST PORTFOLIO
4BATLE ICAV
NEWS ROOM
CONTACT
More

Use tab to navigate through the menu items.

NEWS ROOM

Apr 27

Ray Therapeutics Receives $4M in Funding from the California Institute for Regenerative Medicine

Ray Therapeutics Receives $4M in Funding from the California Institute for Regenerative Medicine

Feb 22

Code Biotherapeutics Announces Collaboration with Takeda

Code Biotherapeutics Announces Collaboration with Takeda

Jan 10

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna

4BIO Capital Portfolio Company Carisma to Collaborate with Moderna

Jan 4

4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics

4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics

Apr 20, 2021

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics

Apr 20, 2021

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

1

2

ARCHIVE

April 2022
March 2022
February 2022
January 2022
December 2021
October 2021
April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020
March 2020
November 2019
September 2019
February 2019
November 2018

SEARCH BY TAGS

FOLLOW US

4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764)

4BIO Partners LLP is an SEC Registered Investment Advisor number 801-121342

© 2015-2022 by 4BIO Partners LLP